Most recent articles on methotrexate in breast cancer

Most recent articles on methotrexate in breast cancer:



HER2 and topoisomerase IIalpha: possible predictors of response to
neoadjuvant chemotherapy for breast cancer patients.
Zhu L, Li YF, Chen WG, He JR, Peng CH, Zhu ZG, Li HW.
Chin Med J (Engl). 2008 Oct 20;121(20):1965-8.

Using response to primary chemotherapy to select postoperative
therapy: long-term results from a prospective phase II trial in
locally advanced primary breast cancer.
Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault
RL, Booser DJ, Valero V, Buzdar AU, Hortobagyi GN.
Clin Breast Cancer. 2008 Dec;8(6):516-21.

Maintenance treatment in metastatic breast cancer.
Sánchez-Muñoz A, Pérez-Ruiz E, Ribelles N, Márquez A, Alba E.
Expert Rev Anticancer Ther. 2008 Dec;8(12):1907-12.

Bevacizumab in combination with metronomic chemotherapy in patients
with anthracycline- and taxane-refractory breast cancer.
García-Sáenz JA, Martín M, Calles A, Bueno C, Rodríguez L, Bobokova J,
Custodio A, Casado A, Díaz-Rubio E.
J Chemother. 2008 Oct;20(5):632-9.

Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal
carcinomatosis in HER2-overexpressing metastatic breast cancer: a case
report.
Stemmler HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Herrmann KA,
Schaffer P, Heinemann V.
Anticancer Drugs. 2008 Sep;19(8):832-6.

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and
weekly paclitaxel in patients with resected high-risk breast cancer: a
Hellenic Cooperative Oncology Group (HeCOG) study.
Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias
A, Fountzilas G.
Cancer Invest. 2008 Jun;26(5):491-8.

Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated
antitumor responses by modulating differentiated T cell localization,
activation and chemokine production in established breast cancer.
Dobrzanski MJ, Reome JB, Hylind JC, Rewers-Felkins KA, Abulsamad K,
Adams SL.
Clin Immunol. 2008 Aug;128(2):205-18.

DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar
outcome for eligible but non-enrolled and randomized breast cancer
patients.
Ejlertsen B, Jensen MB, Mouridsen HT, Andersen J, Cold S, Jakobsen E,
Kamby C, Sørensen PG, Ewertz M.
Acta Oncol. 2008;47(4):709-17.


Adjuvant cyclophosphamide, methotrexate, and fluorouracil in
premonopausal patients with node-positive breast cancer: indirect
comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B, Mouridsen HT, Jensen MB.
Acta Oncol. 2008;47(4):662-71.

Anemia is a significant prognostic factor in local relapse-free
survival of premenopausal primary breast cancer patients receiving
adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M,
Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R,
Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R,
Gnant M; Austrian Breast and Colorectal Cancer Study Group.
Clin Cancer Res. 2008 Apr 1;14(7):2082-7.

Fifteen-year median follow-up results after neoadjuvant doxorubicin,
followed by mastectomy, followed by adjuvant cyclophosphamide,
methotrexate, and fluorouracil (CMF) followed by radiation for stage
III breast cancer: a phase II trial (CALGB 8944).
Kimmick GG, Cirrincione C, Duggan DB, Bhalla K, Robert N, Berry D,
Norton L, Lemke S, Henderson IC, Hudis C, Winer E; Cancer and Leukemia
Group B.
Breast Cancer Res Treat. 2009 Feb;113(3):479-90.

Randomized trial of high-dose adjuvant chemotherapy with autologous
hematopoietic stem-cell support versus standard-dose chemotherapy in
breast cancer patients with 10 or more positive lymph nodes: overall
survival after 6 years of follow-up.
Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N,
Metzner B, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K,
Kreienberg R, Schumacher M, Jonat W.
Ann Oncol. 2008 Jun;19(6):1082-9.















InTextoResearch, Baelen, Wallonie (Wallonia), Belgique (Belgium) &
Agence Wallonne d’Information Scientifique (AWIS) (Marc Lacroix,
scimedweb@xxxxxxxx)
.